Two-season effectiveness of a single nirsevimab dose against RSV hospitalisation in healthy term-born infants: a population-based case-control study, Spain, October 2023 to March 2025.

Saved in:
Bibliographic Details
Title: Two-season effectiveness of a single nirsevimab dose against RSV hospitalisation in healthy term-born infants: a population-based case-control study, Spain, October 2023 to March 2025.
Authors: Núñez O; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain., Juaneda J; Directorate-General for Public Health, Valencia, Valencian Community, Spain., Martinez-Marcos M; Agència de Salut Pública de Catalunya (ASPCAT), Barcelona, Catalonia, Spain., Muñoz Platón E; Directorate-General of Public Health, Toledo, Castilla-La Mancha, Spain., Rivas Wagner E; Directorate-General of Public Health, Canary Islands Health Service, Santa Cruz de Tenerife, Canary Islands, Spain., Santiago-Pérez MI; Directorate-General of Public Health, Department of Health, Santiago de Compostela, Galicia, Spain., Álvarez Río V; Directorate-General of Public Health, Department of Health, Valladolid, Castilla y León, Spain., Zornoza Moreno M; Directorate-General of Public Health and Addictions, Murcia, Region of Murcia, Spain., Fernández Ibáñez A; Directorate-General of Public and Mental Health, Oviedo, Asturias, Spain., Perez Suarez G; Directorate-General of Public Health, Zaragoza, Aragón, Spain., Loroño Ortiz G; Department of Health, Vitoria-Gasteiz, Basque Country, Spain., Egüés N; Instituto de Salud Pública y Laboral de Navarra - IdiSNA, Pamplona, Navarra, Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain., Berradre Sáenz B; Directorate-General of Public Health, Logroño, La Rioja, Spain., Cuesta Franco MLÁ; Directorate-General of Public Health, Mérida, Extremadura, Spain., Casado Cobo S; Directorate-General of Public Health, Santander, Cantabria, Spain., Domínguez Padilla M; University Hospital of Ceuta, Ceuta, Spain., Castrillejo D; Directorate-General of Public Health, Melilla, Spain., Míguez Santiyán A; Directorate-General for Public Health, Valencia, Valencian Community, Spain., Basile L; Agència de Salut Pública de Catalunya (ASPCAT), Barcelona, Catalonia, Spain., Rafael de la Cruz López MÁ; Directorate-General of Public Health, Toledo, Castilla-La Mancha, Spain., Sanabria Curbelo D; Directorate-General of Public Health, Canary Islands Health Service, Santa Cruz de Tenerife, Canary Islands, Spain., Pérez-Martínez O; Directorate-General of Public Health, Department of Health, Santiago de Compostela, Galicia, Spain., Rodríguez Recio MJ; Directorate-General of Public Health, Department of Health, Valladolid, Castilla y León, Spain., Duro Gómez L; Directorate-General of Public Health and Addictions, Murcia, Region of Murcia, Spain., Alonso Vigil MDP; Directorate-General of Public and Mental Health, Oviedo, Asturias, Spain., Mendez Diaz M; Directorate-General of Public Health, Zaragoza, Aragón, Spain., Sancho R; Department of Health, Vitoria-Gasteiz, Basque Country, Spain., Castilla J; Instituto de Salud Pública y Laboral de Navarra - IdiSNA, Pamplona, Navarra, Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain., Ibáñez Pérez AC; Directorate-General of Public Health, Logroño, La Rioja, Spain., Batalla Rebollo N; Directorate-General of Public Health, Mérida, Extremadura, Spain., Sánchez Piorno L; Directorate-General of Public Health, Santander, Cantabria, Spain., López Berrios N; Public Health Department, Ceuta, Spain., Lamas J; University Hospital of Melilla, Melilla, Spain., Olmedo C; Vaccines Division, Directorate-General of Public Health, Ministry of Health, Madrid, Spain., Monge S; These authors contributed equally to the work and share last authorship.; Consortium for Biomedical Research on Infectious Diseases (CIBERINFEC), Madrid, Spain.; National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain., Pastor-Barriuso R; These authors contributed equally to the work and share last authorship.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.
Corporate Authors: Nirsevimab Effectiveness Study Collaborators; The members of the group are listed under collaborators.
Source: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2026 Mar; Vol. 31 (9).
Publication Type: Journal Article
Journal Info: Publisher: European Centre for Disease Prevention and Control (ECDC) Country of Publication: Sweden NLM ID: 100887452 Publication Model: Print Cited Medium: Internet ISSN: 1560-7917 (Electronic) Linking ISSN: 1025496X NLM ISO Abbreviation: Euro Surveill Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1560-7917
DOI:10.2807/1560-7917.ES.2026.31.9.2500593